argenx to Host Autoimmune Myositis R&D Webinar

argenx will host a webinar on June 23, 2026, to discuss advancing FcRn leadership into autoimmune myositis. The company will present data on efgartigimod showing sustained patient benefits in myositis and Sjogren's disease, with management and external key opinion leaders from leading medical institutions participating.

06/23/2026, 1:00 AM • GlobeNewswire

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Sanofi discontinued its Phase 3 MOBILIZE study of riliprubart for CIDP patients due to failure to meet efficacy objectives. The setback highlights trial design challenges in CIDP studies and may strengthen Argenx's Vyvgart market position, which has demonstrated successful trial execution in the same indication.

06/11/2026, 9:09 AM • Benzinga

argenx to Present at Upcoming Investor Conferences

argenx announced that its management team will participate in two major investor conferences in June 2026: the William Blair 46th Annual Growth Stock Conference on June 3 in Chicago and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami. Live webcasts will be available on the company's investor website.

05/27/2026, 1:00 AM • GlobeNewswire

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.

05/18/2026, 1:00 PM • GlobeNewswire

Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

The FDA approved a label expansion for Argenx's VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo to treat all serotypes of adult patients with generalized myasthenia gravis (gMG), including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients. The approval expands the addressable market by 18% and positions the franchise to exceed $5 billion in annual sales with 64% year-over-year growth. ARGX shares rose 2.33% following the announcement.

05/11/2026, 1:37 PM • Benzinga

FDA Expands Approval of VYVGART and VYVGART Hytrulo to All Adults Living with Generalized Myasthenia Gravis

The FDA has expanded approval of VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) to treat all serotypes of adult patients with generalized myasthenia gravis, including seronegative patients who previously had limited treatment options. The approval is based on the Phase 3 ADAPT SERON study, which demonstrated clinically meaningful improvements in patient daily living activities with a consistent safety profile.

05/08/2026, 6:27 PM • GlobeNewswire

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

argenx, a global immunology company, announced it will host a conference call on May 7, 2026 at 2:30 PM CET to discuss its first quarter 2026 financial results and provide a business update. The company is committed to developing novel antibody-based medicines for severe autoimmune diseases.

04/30/2026, 1:00 AM • GlobeNewswire

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

argenx announced positive Phase 3 trial results for VYVGART across multiple myasthenia gravis (MG) subtypes and chronic inflammatory demyelinating polyneuropathy (CIDP) at the 2026 AAN Annual Meeting. ADAPT OCULUS demonstrated VYVGART as the first targeted biologic treatment for ocular MG, while ADAPT SERON showed efficacy across seronegative MG patients. ADHERE analysis supported earlier use of VYVGART Hytrulo in treatment-naïve CIDP patients with 87.5% achieving early benefit. The company also presented Phase 3 trial designs for empasiprubart in CIDP and follow-up data for adimanebart in congenital myasthenic syndromes.

04/18/2026, 1:00 AM • GlobeNewswire

Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP

Folia Health announced a collaboration with argenx to launch a first-of-its-kind at-home observational real-world evidence initiative for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study uses Folia's home-reported outcomes platform to capture symptom severity, treatment utilization, and daily disease management directly from patients and caregivers over a six-month period.

04/07/2026, 10:00 AM • GlobeNewswire

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

RTW Investments established a new $193 million position in Apellis Pharmaceuticals by acquiring 7.67 million shares in Q4 2025. Despite a 29% stock decline over the past year, the investment signals confidence in the company's commercial-stage biotech portfolio, which generated $689 million in product revenue driven by its flagship therapy. The position represents a calculated pivot toward more durable revenue streams within a portfolio focused on high-growth biotech names.

03/21/2026, 7:19 PM • The Motley Fool

Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics

Unnatural Products, a biotech company developing orally-delivered macrocyclic peptides, closed a $45 million Series B funding round led by The Venture Collective. The company also announced a licensing agreement with Novartis worth up to $1.7 billion in total potential milestones for cardiovascular therapeutics. The platform combines attributes of biologics and small molecules to target previously undruggable disease targets.

03/16/2026, 7:00 AM • GlobeNewswire

Vyvgart (Argenx) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Vyvgart (efgartigimod alfa-fcab), an FcRn inhibitor developed by Argenx, is experiencing significant market growth driven by rising autoimmune disease prevalence, regulatory approvals including a March 2024 Japan approval for ITP treatment, and a September 2025 manufacturing partnership with Fujifilm to expand production capacity. The market is expanding beyond generalized myasthenia gravis (gMG) into other indications with growing adoption of precision immunology and personalized treatments, though tariffs are pushing for localized manufacturing investments.

03/13/2026, 8:00 AM • GlobeNewswire

Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney Month

The American Kidney Fund (AKF) is launching its Kidney Month campaign on March 1, 2026, to raise awareness about kidney disease affecting 1 in 7 American adults. The campaign emphasizes early detection and prevention through the 'Kidneys Count' initiative and encourages people to pledge to discuss kidney health with their doctors. AKF will host Kidney Action Week (March 2-5) featuring expert sessions on kidney disease management and treatment options.

02/27/2026, 9:52 AM • GlobeNewswire

Argenx Touts Positive Phase 3 Eye Disease Study Results

Argenx announced positive Phase 3 ADAPT OCULUS study results for VYVGART in treating ocular myasthenia gravis, meeting its primary endpoint with statistically significant improvement in patient-reported outcomes. The company reported strong Q4 earnings of $8.02 per share (beating consensus of $6.02) and sales of $1.32 billion (surpassing consensus of $1.29 billion). The results support a planned FDA supplemental application to expand VYVGART's label into oMG treatment.

02/26/2026, 9:01 AM • Benzinga

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

argenx announced positive Phase 3 results for VYVGART in ocular myasthenia gravis (oMG), meeting its primary endpoint with statistical significance (p=0.012). The study showed significant improvement in ocular symptoms including diplopia and ptosis compared to placebo. The company plans to submit a Supplemental Biologics License Application (sBLA) to the FDA to expand VYVGART's label into oMG, representing the first targeted treatment specifically evaluated for this indication.

02/26/2026, 12:30 AM • GlobeNewswire